

OPORTUNIDADES DE FINANCIACIÓN INTERNACIONAL. IMI, THE THINK BIG AREAS.

XI Conferencia Anual de las Plataformas Tecnológicas de
Investigación Biomédica: Medicamentos Innovadores, Nanomedicina
Tecnología Sanitaria y Mercados Biotecnológicos

Barcelona, 6 de marzo de 2018

ESHORIZONTE  2020

Marta Gómez Quintanilla

Salud, Cambio Demográfico y Bienestar

División de Programas Europeos - Horizonte 2020

DIRECCIÓN DE PROGRAMAS EUROPEOS, ESPACIO
Y RETORNOS TECNOLÓGICOS

marta.gomez@cdti.es | (+34) 91-581.55.62

Centro para el Desarrollo Tecnológico Industrial, E.P.E. | MINECO

Cid, 4 - 28001 Madrid (España) - www.cdti.es



Oportunidades de Financiación Internacional



IMI, The Think Big Areas



Conclusiones



Oportunidades de Financiación Internacional



IMI, The Think Big Areas



Conclusiones



Public-Private Partnership with big Pharma



innovative
medicines
initiative



Public-Public Partnerships with EU Member States & beyond



JPND
research



Blue sky research

Prizes

Education –
R&D - Innovation



European
Research
Council



HORIZON2020
Marie Skłodowska-
Curie actions



Resultados preliminares

Datos salud Elaborado en noviembre 2017

Fuente: Datos Comisión Europea, elaboración CDTI – Base de datos oficial de participación española en el Programa Marco

© CDTI, 2017. Se puede reproducir citando la fuente

INICIATIVA MEDICAMENTOS INNOVADORES	IMI-CALL-2013-9	H2020-PHC-2014-SINGLE-STAGE
	IMI-JU-10-2013	H2020-HCO-2014
	IMI-JU-11-2013	H2020-PHC-2014-TWO-STAGE
	H2020-JTI-IMI2-2014-01-TWO-STAGE	H2020-ADHOC-2014-20 ÉBOLA
	H2020-JTI-IMI2-2014-02-SINGLE-STAGE (ÉBOLA)	H2020-PHC-2015-SINGLE-STAGE_RTD
	H2020-JTI-IMI2-2015-03-TWO-STAGE	H2020-HCO-2015
	H2020-JTI-IMI2-2015-04-TWO-STAGE	H2020-PHC-2015-SINGLE-STAGE_CNECT
	H2020-JTI-IMI2-2015-05-TWO-STAGE	H2020-PHC-2015-TWO-STAGE
	H2020-JTI-IMI2-2015-06-TWO-STAGE	H2020-HOA-01-2015 (PRIZE)
	H2020-JTI-IMI2-2015-07-TWO-STAGE	H2020-PM-2016-JAPAN
	H2020-JTI-IMI2-2015-08-SINGLE-STAGE (PARTE 2016)	H2020-SC1-2016-CNECT
	H2020-JTI-IMI2-2016-09-TWO-STAGE	H2020-SC1-2016-RTD-ZIKA
		H2020-DS-2016
		H2020-SC1-2016-RTD
		H2020-SC1-2017-TWO-STAGE-RTD
TOTAL		H2020-SC1-2017-SINGLE-STAGE_RTD
		H2020-SC1-2017-CNECT-1
		H2020-SC1-2017-CNECT-2
		TOTAL

Convocatorias consideradas

Buenos resultados en Salud, tanto en convocatorias ordinarias como en IMI

Gestión	Área	Presupuesto total (M€)	Subv total (M€)	Subv ES (M€)	% UE	Rank ES
Programa de Trabajo Reto 1	1. Comprender la salud, el bienestar y la enfermedad	341,7	329,5	18,9	6,1%	7º
	2. Prevenir la enfermedad	456,0	397,7	23,2	6,2%	6º
	3. Tratamiento y gestión de enfermedades	646,6	571,6	47,4	8,8%	6º
	4. Envejecimiento activo y autogestión de la salud	161,5	144,3	18,1	13,3%	2º
	5. Métodos y datos	180,8	175,0	17,4	10,5%	4º
	6. Prestación de atención sanitaria y asistencia integrada	246,2	232,6	24,8	11,7%	3º
	7. Otras acciones	258,3	114,1	8,0	7,8%	6º
	TOTAL	2.291,2	1.964,8	157,8	8,6%	5º
IMI	Iniciativa de Medicamentos Innovadores	1.358,5	638,1	51,8	8,4%	5º
TOTAL		3.649,7	2.602,9	209,6	8,6%	5º

Buenos resultados en Salud, tanto en convocatorias ordinarias como en IMI

Gestión	Área	Presupuesto total (M€)	Subv total (M€)	Subv ES (M€)	% UE	Rank ES
Programa de Trabajo Reto 1						
	TOTAL	2.291,2	1.964,8	157,8	8,6%	5º
	IMI	1.358,5	638,1	51,8	8,4%	5º
TOTAL		3.649,7	2.602,9	209,6	8,6%	5º



Oportunidades de Financiación Internacional



IMI, The Think Big Areas



Conclusiones

Iniciativa de Medicamentos Innovadores 2

<http://www.imi.europa.eu/about-imi>



Mejorar el proceso de elaboración de medicamentos: un apoyo más eficaz a la cooperación en I+D+I entre academia, PYME y sector biofarma, que los pacientes dispongan de medicamentos mejores y más seguros.


Convocatorias abiertas y previstas - 2018

www.imi.europa.eu/content/future-topics



	Referencia CE	Fecha apertura	Fecha cierre	Presupuesto	Contenidos, tipos de actividades y observaciones
	H2020-JTI-IMI2-2015-08-SINGLE-STAGE	15/09/16	16/03/17 & 14/09/17 & 15/03/18	55,25668	1 topic (Ébola+filovirus), R&I (+ M€ EFPIA/industria). Cut-off dates 16/03 y 14/09/2017 + Cut-off date 15/03/2018
	H2020-JTI-IMI2-2017-13	30/11/17	28/02/18 (2ª fase 05/09/18)	106,6 M€	15 topics (varios temas), R&I & CSA (+ 116,4 M€ EFPIA+otros)
	H2020-JTI-IMI2-2017-14		14/06/18 (2ª fase 11/12/18) 15/03/18	82,3 M€?	¿4 topics (varios temas), R&I (+ 82,3 M€ EFPIA+otros) ?
	H2020-JTI-IMI2-2017-15	18/07/18 ??	24/10/18 (2ª fase 15/05/19)	¿132 M€?	¿X topics posibles (varios temas), R&I & CSA (+ 132 M€ EFPIA) ?

Todas las entidades pueden participar



Eligibles para recibir financiación



- Instituciones académicas
- Organizaciones sin ánimo de lucro
- **PYMEs**
- **Empresas medianas (≤ 500 M€ turnover)**
- Organizaciones internacionales de interés europeo

- Establecidos en Estados Miembros o Países Asociados
- **Otros países: Sin financiación** salvo que se determine esencial su participación por parte de IMI
- Hasta 100%* costes indirectos (RIA/CSA) + 25% indirectos
- **Reglas especiales IPRs**

Contribución en especie/en €

EFPIA members


>1.425 M€

+ Associated partners

+ Partner in research

www.efpia.eu/about-us/membership

Other > 213 M€



Contribución en especie/en €

EFPIA members >1.425 M€

+ Associated partners



+ Partner in research →

www.efpia.eu/about-us/membership



Contribución en especie/en €


- Accelerate Diagnostics
- Autism Speaks
- Autistica
- BD Switzerland Sarl
- Bill and Melinda Gates Foundation
- Bio-rad Laboratories
- International Diabetes Federation
- JDRF
- Leona M. and Harry B. Helmsley Charitable Trust
- Medicines for Malaria Venture (MMV)
- Parkinson UK
- Simons Foundation Autism Research Initiative (SFARI)
- Software AG
- T1D Exchange
- Wellcome Trust

Other > 213 M€

<http://www.imi.europa.eu/get-involved/associated-partners>

The Interim Evaluation of the Innovative Medicines Initiative 2 Joint Undertaking (2014-2016) operating under Horizon 2020 Experts Group Report

(https://ec.europa.eu/research/health/pdf/imi2_interim_evaluation.pdf)




RECOMMENDATIONS FOR IMI2 JU

1. Attract and integrate other industries.
2. Attract more SMEs.
3. SMART KPIs.
4. Review the IP policy and make it more flexible.
5. Access to project outcomes and assure sustainability.

The Interim Evaluation of the Innovative Medicines Initiative 2 Joint Undertaking (2014-2016) operating under Horizon 2020 Experts Group Report

(https://ec.europa.eu/research/health/pdf/imi2_interim_evaluation.pdf)



RECOMMENDATIONS FOR FUTURE IMI JU INITIATIVES


1. Engagement of other industry sectors with the pharmaceutical industry.
2. Increase the transparency:
 - of in-kind contributions
 - SRA
 - call topics generation to reflect European interest and interests of stakeholders other than EFPIA.
3. Change the rules on the calculation of the in-kind contributions from non-European entities.

¿Cómo se generan los *topics*?


www.imi.europa.eu/about-imi/how-imi-works



HOW IMI CALL TOPICS ARE GENERATED



HOW IMI CALL TOPICS ARE GENERATED



Strategic Research Agenda

www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI2_SRA_March2014.pdf



The right prevention and treatment
for the right patient at the right time
Strategic Research Agenda for
Innovative Medicines Initiative 2



- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



Annual Work Plan

www.imi.europa.eu/reference-documents#reference-doc-collapsible-4



Annual Work Plan and Budget for 2018

Copyright © 2017 Innovative Medicines Initiative

In accordance with Article 16 of the Statutes of the IMI2 JU annexed to Council Regulation (EU) No 557/2014 of 6 May 2014 and with Article 31 of the Financial Rules of the IMI2 JU.

The Annual Work Plan will be made publicly available after its adoption by the Governing Board.

**Annex to the Decision of the IMI2 JU Governing Board
No. IMI2-GB-DEC-2017-26 adopted on 15.12.2017**

2.2.2	Scientific priorities for 2018	
A.	Diabetes/Metabolic disorders	
B.	Neurodegeneration and other Neuroscience Priorities	
C.	Immunology	
D.	Infection control including vaccines	
E.	Translational safety	
F.	Big data, digital health, clinical trials and regulatory research	
G.	Oncology	
H.	Facilitating the translation of advanced therapies to patients in Europe	
	<i>Calls for Proposals</i>	



Grupos industriales para la definición de topics: Strategic Governing Groups (SGGs)

<http://www.imi.europa.eu/about-imi/governance/strategic-governing-groups>

+ IMMUNOLOGY

+ DIABETES / METABOLIC DISORDERS

+ NEURODEGENERATION

+ TRANSLATIONAL SAFETY

+ DIGITAL HEALTH AND PATIENT-CENTRIC EVIDENCE GENERATION **New/evolution**

+ INFECTIONS CONTROL

+ ONCOLOGY

Cross-cutting issues

www.imi.europa.eu/get-involved/submit-your-ideas



SUBMIT YOUR
IDEAS

Think Big process – summary

- ✳ Global Heads of R&D drive definition of key priority research areas that will make the best use of the remaining IMI2 public and private investment
- ✳ Commitments expected in 2018-2020:
 - ✳ Public funding for grants for public partners: ca EUR 850 mln
 - ✳ In-kind investment by companies: ca EUR 900 mln
- ✳ Four areas prioritised
 - ✳ AMR
 - ✳ Immunology
 - ✳ Digital health
 - ✳ Modernisation of clinical trials



Identification of topics

European
Commission

Coordinated by
IMI Programme Office

EFPIA

Draft topic text



The screenshot shows the IMI website with the URL www.imi.europa.eu/apply-funding/future-topics. The page features the IMI logo and the text "Europe's partnership for health". The navigation bar includes links for Home, About IMI, Get involved, Apply for funding, Projects & results, News & events, and Reference documents. The main content area is titled "Future topics" and includes social media icons for Facebook, Twitter, and LinkedIn. The text explains that IMI regularly publishes draft topic texts and provides information on how to stay updated. It also lists four topics currently under consideration for inclusion in future IMI Calls for proposals.

Home | [Apply for funding](#) | Future topics

Future topics

To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes draft topic texts on this page several weeks before the official Call launch. To ensure you get the latest information on forthcoming Calls, sign up to our [newsletter](#), follow us on [Twitter](#), or join our [LinkedIn group](#).

Draft topic texts are subject to consultations involving IMI's States Representatives Group, Scientific Committee, and the European Commission. They must also be approved by the IMI Governing Board. Depending on the results of the consultations and approval process, the final topic text may differ significantly from the draft versions initially published here, and some topics may not be included in a Call in the end.

The following topics are currently under consideration for inclusion in future IMI Calls for proposals:

- [Targeted immune intervention for treatment of non-response and remission](#)
- [Non-invasive clinical molecular imaging of immune cells](#)
- [Development of a platform for federated and privacy-preserving machine learning in support of drug discovery](#)
- [Centre of excellence – remote decentralised clinical trials](#)

We encourage the participation of SMEs in our projects. [This presentation](#) highlights elements of the current indicative Call topics that could be

Draft topic text



**IMI STATES
REPRESENTATIVES
GROUP**

CONSULTATION

**IMI SCIENTIFIC
COMMITTEE**



**IMI Governing Board approval of
Call documents**



CALL LAUNCH

IMI – Think Big ideas



DESCARGO DE RESPONSABILIDAD:

Esto son las ideas que se están barajando en este momento por parte de EFPIA, no constituye ningún compromiso. Las convocatorias se publicarán en el Portal del Participante, así como en el Diario Oficial de la UE y serán los únicos documentos válidos.

Think Big ideas



*Immunology

- * Targeted immune intervention for treatment of non-response and remission
- * Non-invasive molecular imaging of immune cells
- * Characterisation of human immunology mechanisms
- * Early disease interception of immune dependent disease
- * Emerging technologies and tools for interrogating human immunobiology

*Antimicrobial Resistance

- * AMR Accelerators (including TB)
- * AMR CT networks

DESCARGO DE RESPONSABILIDAD:

Esto son las ideas que se están barajando en este momento por parte de EFPIA, no constituye ningún compromiso. Las convocatorias se publicarán en el Portal del Participante, así como en el Diario Oficial de la UE y serán los únicos documentos válidos.

Think Big ideas

* Digital Health and Modernisation of clinical trials

- * Centre of excellence - decentralized, remote clinical trials
- * Integrated Research Platforms
- * Digital Transformation of Clinical Trials Endpoints
- * Digital support to compliance and adherence
- * Blockchain technologies in pharma processes

DESCARGO DE RESPONSABILIDAD:

Esto son las ideas que se están barajando en este momento por parte de EFPIA, no constituye ningún compromiso. Las convocatorias se publicarán en el Portal del Participante, así como en el Diario Oficial de la UE y serán los únicos documentos válidos.

Think Big ideas planned for launch in 2018

Immuno:

Treatment of non-response and remission

Better control of immune related diseases.
Improved patient management /personalized treatment by validation of predictive biomarkers for non-response and remission

Immuno:

Non-invasive molecular imaging of immune cells

Generation and validation of in-vivo immuno-probes as non-invasive early indicators of efficacy and outcomes for multiple disorders including Cancer, RA, Asthma, IBD, MS, Alzheimer's, etc.

AMR:

Accelerator of AMR R&D

Enhance overall industry/SME/academia success in AMR discovery and progress assets/programs

DESCARGO DE RESPONSABILIDAD:

Esto son las ideas que se están barajando en este momento por parte de EFPIA, no constituye ningún compromiso. Las convocatorias se publicarán en el Portal del Participante, así como en el Diario Oficial de la UE y serán los únicos documentos válidos.

Think Big Ideas planned for launch in 2018

Digital:

Remote clinical trials

Bringing clinical research to patient as a new paradigm for running clinical trials. Combined with the adoption of digital endpoints, the flexibility of patient follow-up during clinical trials could reduce working costs in centralized hospitals, increase the frequency of data collection, increase data quality amongst others.

Digital:

Biosensors/digital endpoints in clinical trials

New digital endpoints that take advantage of novel biosensor technology to increase the accuracy of endpoint so that data can be included in the label and be used in the market to monitor real world value.

Clinical trials:

Integrated Research Platforms

Platform trials are already delivering time and cost savings. Groups setting up platform trials face common challenges. We propose to (i) develop best practices and (ii) enable the set up of several IRPs in diseases of common interest.

DESCARGO DE RESPONSABILIDAD:

Esto son las ideas que se están barajando en este momento por parte de EFPIA, no constituye ningún compromiso. Las convocatorias se publicarán en el Portal del Participante, así como en el Diario Oficial de la UE y serán los únicos documentos válidos.



Oportunidades de Financiación Internacional



IMI, The Think Big Areas



Conclusiones

Calendario de actuaciones- AWP

Como representante ES miembro del IMI States Representatives Group



2013	2014	2015	2016	2017	2018	2019	2020
Draft AWP	AWP 2014	AWP 2015					
	Update calls	Update calls	AWP 2016	AWP 2017			
			Update calls	Update calls	AWP 2018	AWP 2019	AWP 2020
					Update call 14 + call 15	Update calls	Update calls

Publicar convocatoria 14
Actualizar convocatoria 15
Preparar AWP 2019
Propuesta CE FP9

Public-Private
Partnership with
big Pharma



Actualizar AWP y publicar convocatorias
Versión avanzada FP9 – IMI3??

Actualizar AWP y publicar convocatorias
– Aprobación FP9 – IMI3??

2013	2014	2015	2016	2017	2018	2019	2020
Draft WP1	Work Programme 2014-2015						
	Update 2015 + ideas 2016-2017	Draft WP2	WP 2016-2017				
			Update 2017 + ideas 2018-2020	Draft WP3	WP 2018-2019 + 2020		
					Update 2019 + ideas 2020	Update 2020	

Collaborative R&I projects

[illegible]

Borrador WP 2021-¿? – Aprobación FP9

Comentarios bienvenidos




Conv. Reto 1 H2020: WP 2019 + WP 2020 + FP9

Conv. IMI2: AWP 2018 + AWP 2019 + AWP 2020 + IMI3

marta.gomez@cdti.es

CONSULTA ABIERTA MINECO SOBRE EL FP9: fp9@mineco.es



El entorno ha cambiado y está en evolución → hacia el próximo Programa Marco / IMI3

CONSULTATION

Public consultation on EU funds in the area of investment, research & innovation, SMEs and single market

https://ec.europa.eu/info/consultations/public-consultation-eu-funds-area-investment-research-innovation-smes-and-single-market_en


Cierra el 8/marzo

Call for feedback on missions

Cierra el 3/abril

<https://ec.europa.eu/eusurvey/runner/482a79de-3fad-17e1-c60d-2e4418c1a95d>





“No es la especie más fuerte la que sobrevive, ni la más inteligente, sino la que mejor se adapta a los cambios”

Charles Darwin



CONTACTO:

Marta Gómez Quintanilla
Spanish Representative - HEALTH
Spanish Representative - IMI
Spanish MB Member - JPND

☎ 34 91 581 55 62 / 00

[marta.gomez\[at\]cdti.es](mailto:marta.gomez[at]cdti.es) - www.cdti.es

✉ <http://bit.ly/1nj1ToZ>

🐦 @EsHorizonte2020
@EU_RDI_LifeSci

¿Quiénes somos? Equipo Salud H2020 CDTI



División
Programas de la UE



Centro para el
Desarrollo
Tecnológico
Industrial

**Marta Gómez
Quintanilla**

(Representante)

marta.gomez@cdti.es

Carolina Carrasco

(NCP- Punto Nacional de Contacto)

carolina.carrasco@cdti.es

Marta de Diego

(Experta IMI)

marta.dediego@cdti.es

☎ 915815562



H2020 - Reto 1 - Gestión ES

- Definición Programas
- Vigilancia



**Apoyo
participación**

GLOSSARY & LINKS

- **AAL:** Ambient Assisted Living www.aal-europe.eu /Active and Assisted Living
- **COCIR:** European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry www.cocir.org
- **EC:** European Commission <http://ec.europa.eu>
- **EDCTP:** The European and Developing Countries Clinical Trials Partnership www.edctp.org
- **EJP:** European Joint Programme
<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/other/index.html>
- **EFPIA:** The European Federation of Pharmaceutical Industries and Associations www.efpia.eu
- **EIP:** European Innovation Partnership http://ec.europa.eu/research/innovation-union/index_en.cfm?pg=eip
- **EIT:** European Institute of Innovation & Technology <http://eit.europa.eu>
- **EMPIR:** European Metrology Programme for Innovation and Research www.emrponline.eu
- **FET:** Future and Emerging Technologies
- **HBP:** Human Brain Project www.humanbrainproject.eu
- **IMI:** Innovative Medicines Initiative www.imi.europa.eu
- **JPI AMR:** Joint Programming in Antimicrobial Resistance www.jpiamr.eu
- **JPI HD&HL:** A Healthy diet for a healthy life www.healthydietforhealthylife.eu
- **JPI MYBL:** Joint Programming More Years, Better Lives www.jp-demographic.eu
- **JPI:** Joint Programming Initiative http://ec.europa.eu/research/era/areas/programming/joint_programming_en.htm
- **JPND:** Joint Programming in Neurodegenerative Research www.neurodegenerationresearch.eu
- **KIC:** Knowledge and Innovation Community <http://eit.europa.eu/kics>
- **PPP:** Public-Private Partnership & **P2P:** Public-Public Partnership
http://ec.europa.eu/research/era/partnership/partnering_en.htm
- **SBIR:** Small Business Innovation Research www.sbir.gov
- **SIA:** Strategic Implementation Agenda / **SIP:** Strategic Implementation Plan
- **SME:** Small and medium-sized enterprises http://ec.europa.eu/enterprise/policies/sme/index_en.htm